bioAffinity Technologies, Inc. will show two posters about its CyPath® Lung test at the 2026 NAVREF Annual Conference.

Sep 22, 2026, 8:34 AM ETPaperworkRead the original at sec.gov

Neutral

The filing says it will present two posters about CyPath Lung at the NAVREF conference. It gives visibility but reports no new clinical results, funding, or approvals, so it does not change the company's prospects.

BIAF · bioAffinity Technologies, Inc.

AI read · Neutral

The AI's read

Presenting posters at a conference raises visibility with veterans and military health researchers. The filing gives no new clinical results, regulatory progress, funding, or commercial partnerships, so it does not change the company's prospects.

Get alerts for BIAF

Follow bioAffinity Technologies, Inc. (BIAF) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BIAF

Free on the App Store and Google Play, or on the web.